FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063960686> ?p ?o ?g. }

• W2063960686 endingPage "257" @default.
• W2063960686 startingPage "251" @default.
• W2063960686 abstract "Using conventional treatment methods for the treatment of clinically localized prostate cancer central axis doses must be limited to 65-70 Gray (Gy) to prevent significant damage to nearby normal tissues. A fundamental hypothesis of three-dimensional conformal radiation therapy (3DCRT) is that, by defining the target organ(s) accurately in three dimensions, it is possible to deliver higher doses to the target without a significant increase in normal tissue complications. This study examines whether this hypothesis holds true and whether a simple modification of treatment technique can reduce the incidence of late rectal morbidity in patients with prostate cancer treated with 3DCRT to minimum planning target volume (PTV) doses of 71-75 Gy.The 257 patients with clinically localized prostate cancer who completed 3DCRT by December 31, 1993 and received a minimum PTV dose of 71-75 Gy are included in this report. The median follow-up time was 22 months (range: 4-67 months); 98% of patients had follow-up of longer than 12 months. The calculated dose at the center of the prostate was < 74 Gy in 19 patients, 74-76 Gy in 206 patients, and > 76 Gy in 32 patients. Late rectal morbidity was graded according to the Late Effects Normal Tissue (LENT) scoring system. Eighty-eight consecutive patients were treated with a rectal block added to the lateral fields. In these patients the posterior margin from the prostate to the block edge was reduced from the standard 15 to 5 mm for the final 10 Gy, which reduced the dose to portions of the anterior rectal wall by approximately 4-5 Gy. Estimates of rates for rectal morbidity were determined by Kaplan-Meier actuarial analysis. Differences in morbidity percentages were evaluated by the Pearson chi-square test.Grade 2-3 rectal morbidity developed in 46 out of 257 patients (18%) and in the majority of cases consisted of rectal bleeding. No patient has developed Grade 4 or 5 rectal morbidity. The actuarial rate of Grade 2-3 morbidity is 23% at 24 months and the median time to the development of Grade 2-3 complications is 15 months. A statistically significant dose effect is evident. The incidence of Grade 2-3 rectal morbidity increased as the dose at the center of the prostate increased (p = 0.05). In patients receiving minimum PTV doses of < or = 76 Gy the use of a rectal block significantly reduced the incidence of Grade 2-3 toxicity; 6 out of 88 (7%) with a block vs. 30 out of 137 (22%) without a block, (p = 0.003).The incidence of late rectal morbidity with 3DCRT to minimum PTV doses of 71-75 Gy is acceptable and to date no Grade 4-5 rectal morbidities have been observed. In our experience, higher doses to the center of the prostate are associated with an increased likelihood of developing Grade 2-3 rectal morbidity but treatment techniques that reduce the total dose to the anterior rectal wall have reduced the incidence of late rectal morbidity. If clinical studies indicate improved tumor control with minimum PTV doses above 71 Gy, then dose escalation above 76 Gy to the center of the prostate should be pursued cautiously with treatment techniques that limit the total dose to the anterior rectal wall." @default.
• W2063960686 created "2016-06-24" @default.
• W2063960686 creator A5038274786 @default.
• W2063960686 creator A5042766411 @default.
• W2063960686 creator A5050591671 @default.
• W2063960686 creator A5078382635 @default.
• W2063960686 creator A5089628955 @default.
• W2063960686 date "1996-05-01" @default.
• W2063960686 modified "2023-09-25" @default.
• W2063960686 title "Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect" @default.
• W2063960686 cites W185255945 @default.
• W2063960686 cites W1965484982 @default.
• W2063960686 cites W1984651023 @default.
• W2063960686 cites W1993181535 @default.
• W2063960686 cites W2060085759 @default.
• W2063960686 cites W2065184437 @default.
• W2063960686 cites W2066875539 @default.
• W2063960686 cites W2069140615 @default.
• W2063960686 cites W2071238711 @default.
• W2063960686 cites W2072846282 @default.
• W2063960686 cites W2076251353 @default.
• W2063960686 cites W2091346187 @default.
• W2063960686 cites W2137900501 @default.
• W2063960686 cites W4293241248 @default.
• W2063960686 doi "https://doi.org/10.1016/0360-3016(96)00064-8" @default.
• W2063960686 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8635930" @default.
• W2063960686 hasPublicationYear "1996" @default.
• W2063960686 type Work @default.
• W2063960686 sameAs 2063960686 @default.
• W2063960686 citedByCount "170" @default.
• W2063960686 countsByYear W20639606862012 @default.
• W2063960686 countsByYear W20639606862013 @default.
• W2063960686 countsByYear W20639606862016 @default.
• W2063960686 countsByYear W20639606862017 @default.
• W2063960686 countsByYear W20639606862018 @default.
• W2063960686 countsByYear W20639606862019 @default.
• W2063960686 countsByYear W20639606862020 @default.
• W2063960686 countsByYear W20639606862021 @default.
• W2063960686 crossrefType "journal-article" @default.
• W2063960686 hasAuthorship W2063960686A5038274786 @default.
• W2063960686 hasAuthorship W2063960686A5042766411 @default.
• W2063960686 hasAuthorship W2063960686A5050591671 @default.
• W2063960686 hasAuthorship W2063960686A5078382635 @default.
• W2063960686 hasAuthorship W2063960686A5089628955 @default.
• W2063960686 hasConcept C121608353 @default.
• W2063960686 hasConcept C126322002 @default.
• W2063960686 hasConcept C126838900 @default.
• W2063960686 hasConcept C126894567 @default.
• W2063960686 hasConcept C141071460 @default.
• W2063960686 hasConcept C201645570 @default.
• W2063960686 hasConcept C2776235491 @default.
• W2063960686 hasConcept C2780192828 @default.
• W2063960686 hasConcept C2781074409 @default.
• W2063960686 hasConcept C2989005 @default.
• W2063960686 hasConcept C509974204 @default.
• W2063960686 hasConcept C526805850 @default.
• W2063960686 hasConcept C71924100 @default.
• W2063960686 hasConceptScore W2063960686C121608353 @default.
• W2063960686 hasConceptScore W2063960686C126322002 @default.
• W2063960686 hasConceptScore W2063960686C126838900 @default.
• W2063960686 hasConceptScore W2063960686C126894567 @default.
• W2063960686 hasConceptScore W2063960686C141071460 @default.
• W2063960686 hasConceptScore W2063960686C201645570 @default.
• W2063960686 hasConceptScore W2063960686C2776235491 @default.
• W2063960686 hasConceptScore W2063960686C2780192828 @default.
• W2063960686 hasConceptScore W2063960686C2781074409 @default.
• W2063960686 hasConceptScore W2063960686C2989005 @default.
• W2063960686 hasConceptScore W2063960686C509974204 @default.
• W2063960686 hasConceptScore W2063960686C526805850 @default.
• W2063960686 hasConceptScore W2063960686C71924100 @default.
• W2063960686 hasIssue "2" @default.
• W2063960686 hasLocation W20639606861 @default.
• W2063960686 hasLocation W20639606862 @default.
• W2063960686 hasOpenAccess W2063960686 @default.
• W2063960686 hasPrimaryLocation W20639606861 @default.
• W2063960686 hasRelatedWork W1971464107 @default.
• W2063960686 hasRelatedWork W1980188241 @default.
• W2063960686 hasRelatedWork W1980245127 @default.
• W2063960686 hasRelatedWork W2091989447 @default.
• W2063960686 hasRelatedWork W2127440557 @default.
• W2063960686 hasRelatedWork W2150621467 @default.
• W2063960686 hasRelatedWork W2590008096 @default.
• W2063960686 hasRelatedWork W2897445903 @default.
• W2063960686 hasRelatedWork W3082324229 @default.
• W2063960686 hasRelatedWork W4315647262 @default.
• W2063960686 hasVolume "35" @default.
• W2063960686 isParatext "false" @default.
• W2063960686 isRetracted "false" @default.
• W2063960686 magId "2063960686" @default.
• W2063960686 workType "article" @default.